Breaking the Barrier to an HIV Vaccine

打破艾滋病毒疫苗的障碍

• 批准号: 10708819
• 负责人: Sara Sawyer
• 金额: $ 109.55万
• 依托单位: UNIVERSITY OF COLORADO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708819
• 关键词: Animal Model; Development; HIV; HIV Infections; HIV vaccine; HIV-1; HIV/AIDS; Human body; Immune; Macaca; Modeling; Monkeys; Persons; Pharmaceutical Preparations; Primates; System; Testing; Vaccines; Viral reservoir; Virus Latency; acute infection; cross immunity; model organism; pandemic disease; tool; vaccine candidate; vaccine development; viral transmission

PROJECT SUMMARY HIV remains the most consequential zoonosis of the last century, with 36 million fatalities and another 37 million infected. Even today, almost 2,000 people per day die of HIV/AIDS globally. Medications are reducing the effects of HIV on the human body and transmission of the virus to others. However, 40 years into the pandemic, there are no vaccines. Effective HIV vaccines remain our only hope of ending the HIV/AIDS pandemic once and for all. HIV vaccines are mostly developed in macaque monkeys, although this primate model of HIV infection has many limitations. Here, we explore a new animal model for HIV infection that recapitulates all key milestones in HIV acute infection and in the establishment of the latent viral reservoir. We develop the tools necessary to turn this into the long-sought model for HIV vaccine development. This new animal model will provide the perfect system to study the immune correlates of protection, the breadth of cross-protection against different HIV-1 subtypes, and to test and develop vaccine candidates.

项目摘要 艾滋病毒仍然是上个世纪最严重的人畜共患疾病，有3600万人死亡，另有3700万人死亡 感染了即使在今天，全球每天仍有近2 000人死于艾滋病毒/艾滋病。药物正在减轻 艾滋病病毒对人体和病毒传播给他人。然而，大流行40年来， 没有疫苗。有效的艾滋病毒疫苗仍然是我们一劳永逸地结束艾滋病毒/艾滋病流行病的唯一希望 所有.艾滋病毒疫苗大多是在猕猴中开发的，尽管这种艾滋病毒感染的灵长类动物模型 很多限制。在这里，我们探索了一种新的HIV感染动物模型，它概括了HIV感染的所有关键里程碑。 艾滋病病毒急性感染并在体内建立潜伏的病毒库。我们开发必要的工具， 这是一个长期寻求的艾滋病毒疫苗开发模式。这种新的动物模型将提供完美的 系统研究免疫相关的保护，对不同的HIV-1交叉保护的广度 亚型，并测试和开发候选疫苗。